ReviewEuropean thyroid journal2026
lncRNAs: a new generation of targets and biomarkers in thyroid cancer.
Review in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) are untranslated RNA molecules that regulate gene expression through diverse mechanisms, acting as scaffolds, guides, decoys, or signals. In thyroid cancer, the most prevalent endocrine malignancy, lncRNAs are increasingly recognized as key contributors to tumor development and progression. Elucidating these molecular mechanisms is essential for advancing diagnostic, prognostic, and therapeutic strategies. This review highlights major lncRNAs implicated in thyroid cancer, categorizing them as upregulated/oncogenes or downregulated/tumor suppressors and describing their mechanisms of action and interactions. lncRNAs are typically expressed at low levels and tightly regulated to preserve normal cell behavior. In thyroid cancer, they serve as crucial regulators of oncogenesis, frequently acting as competing endogenous RNAs that influence key signaling pathways. While most studies focus on miRNA sponging, other mechanisms are underexplored. Circulating lncRNAs offer potential for non-invasive diagnostics, and several lncRNAs show promise as therapeutic targets. Thus, continued research into the diverse functions of lncRNAs is vital to fully harness their clinical potential in thyroid cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.